Eli Lilly's weight-loss drug is no longer on the Food and Drug Administration's drug shortage list. Compounding pharmacies say this will limit patient access.

The one problem Lilly has faced is meeting the soaring demand for these products. In fact, they are so popular that the U.S. Food and Drug Administration (FDA) placed tirzepatide on its drug shortage list two years ago -- demand had outstripped supply.

In accepting the FDA’s motion, U.S. District Judge Mark Pittman put on hold a lawsuit filed by the Outsourcing Facilities Association (OFA), which called the FDA’s decision to remove tirzepatide from the shortage list a “reckless and arbitrary decision—lacking any semblance of lawful process.”

The two-year shortage of Eli Lilly’s blockbuster weight-loss and diabetes drugs is over, the U.S. Food and Drug Administration announced Wednesday.

While artificial intelligence (AI) has been one of the hottest investing trends, GLP-1 weight loss drugs are a close second. Demand for Eli Lilly's Mounjaro and Zepbound remains robust, and sell-side analysts tracking script data shows strong growth for both of these drugs.

The FDA confirmed Thursday that Eli Lilly has increased production of its blockbuster weight-loss drug Zepbound and type 2 diabetes drug Mounjaro, implying the company can now supply enough doses to meet current demand.

Pharmacists can continue making compounded versions of generic tirzepatide, the active ingredient in popular medications Mounjaro and Zepbound, the FDA said in a recent court filing.